Global biotech Shire ViroPharma has launched legal action against vaccines and blood products supplier CSL, claiming a new treatment for hereditary angioedema, CSL 830, infringes a Shire ViroPharma patent.
Hereditary angioedema is an inherited deficiency of a blood protein which cause episodes of swelling in parts of the body.
CSL said Shire ViroPharma has filed a complaint in the US District Court for the District of Delaware, alleging infringement of a newly granted US patent for a treatment of hereditary angioedema.
"CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims," it said in a statement.
The US Food and Drug Administration started to assess CSL's licence application for CSL830 in August 2016, and subject to FDA approval, CSL expects to make the new therapy available to patients later this year.
Shares in CSL were down 76 cents at $127.71 at 1105 AEST.
Share
